The stock price of American biotech company Tempest Therapeutics Inc. skyrocketed after announcing the latest research progress in treating liver cancer.
On Wednesday, October 11th EST, $Tempest Therapeutics (TPST.US)$The short jump was nearly 788%, and the increase continued to expand thereafter. At the close, the increase was more than 3970%, up nearly 40 times in one day. As of Wednesday's close, Tempest's stock price had increased by about 750% this year, and the S&P 500 rose by about 14% during the same period.
Earlier on Wednesday, Tempest announced that the company's investigational drug candidate TPST-1120 showed the superiority of clinical treatment in first-line treatment for a common type of liver cancer — unresectable hepatocellular carcinoma (UHCC) — after being used in combination with Roche's two therapeutic drugs, tecentriq and Avastin. $Tesla (TSLA.US)$ $Microsoft (MSFT.US)$
According to Tempest, the median time of disease-free survival (PFS) for UHCC patients after receiving the combination therapy of the above three drugs was 7 months, while the median PFS for UHCC patients receiving only Tecentriq and Avastin combined treatment was 4.3 months.According to this estimate, the patient's disease-free survival time increased by more than 60%.
The above test results are from the random distribution of pairs to T...